The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progression

Journal of Neuroscience Research

Volumn 88, Issue 16, 2010, Pages 3566-3577

  Di Domenico, Fabio ^a   Owen, Joshua B ^b   Sultana, Rukhsana ^b   Sowell, Rena A ^b   Perluigi, Marzia ^a   Cini, Chiara ^a   Cai, Jian ^c   Pierce, William M ^c   Butterfield, D Allan ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Alzheimer's disease; Amnestic mild cognitive impairment; Lectin affinity chromatography; Mass spectrometry; Proteomics; Wheat germ agglutinin

Indexed keywords

AGGLUTININ; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA GLUCOSIDASE; BETA SYNUCLEIN; CALMODULIN; CALRETICULIN; GELSOLIN; GLUTAMATE DEHYDROGENASE; GLYCOPROTEIN GP 96; NEURON SPECIFIC ENOLASE; PROTEIN DISULFIDE ISOMERASE; PROTEOME; TRANSFER RNA METHYLTRANSFERASE; TROPOMYOSIN;

AFFINITY CHROMATOGRAPHY; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENDOPLASMIC RETICULUM; FEMALE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEOTIDE SEQUENCE; PARIETAL LOBE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEOMICS; WHEAT GERM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CHROMATOGRAPHY, AFFINITY; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; GLYCOSYLATION; HIPPOCAMPUS; HUMANS; MALE; MATCHED-PAIR ANALYSIS; NERVE TISSUE PROTEINS; PARIETAL LOBE; PROTEOME; REFERENCE VALUES; WHEAT GERM AGGLUTININS;

EID: 78049431249     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22528     Document Type: Article

References (67)

1. Abraham CR, Potter H. 1989a. Alpha 1-antichymotrypsin in brain aging and disease. Prog Clin Biol Res 317: 1037-1048.
2. Abraham CR, Potter H. 1989b. The protease inhibitor, alpha 1-antichymotrypsin, is a component of the brain amyloid deposits in normal aging and Alzheimer's disease. Ann Med 21: 77-81.
3. Abraham CR, Selkoe DJ, Potter H. 1988. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52: 487-501.
4. Aksenova MV, Aksenov MY, Butterfield DA, Carney JM. 1996. Alpha-1-antichymotrypsin interaction with A beta (1-40) inhibits fibril formation but does not affect the peptide toxicity. Neurosci Lett 211: 45-48.
5. Aksenov MY, Aksenova MV, Carney JM, Butterfield DA. 1996. Alpha 1-antichymotrypsin interaction with A beta (1-42) does not inhibit fibril formation but attenuates the peptide toxicity. Neurosci Lett 217: 117-120.
6. Boguski MS, McIntosh MW. 2003. Biomedical informatics for proteomics. Nature 422: 233-237.
7. Booth C, Koch GL. 1989. Perturbation of cellular calcium induces secretion of luminal ER proteins. Cell 59: 729-737.
8. Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, Klein JB, Butterfield DA. 2005. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 132: 313-324.
9. Butterfield DA, Lange ML. 2009. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem 111: 915-933.
10. Butterfield DA, Sultana R. 2007. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis 12: 61-72.
11. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, Sultana R. 2006. Pin1 in Alzheimer's disease. J Neurochem 98: 1697-1706.
12. Cecarini V, Ding Q, Keller JN. 2007. Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radic Res 41: 673-680.
13. Clower DM, West RA, Lynch JC, Strick PL. 2001. The inferior parietal lobule is the target of output from the superior colliculus, hippocampus, and cerebellum. J Neurosci 21: 6283-6291.
14. Cole RN, Hart GW. 2001. Cytosolic O-glycosylation is abundant in nerve terminals. J Neurochem 79: 1080-1089.
15. Comer FI, Hart GW. 2000. O-Glycosylation of nuclear and cytosolic proteins. Dynamic interplay between O-GlcNAc and O-phosphate. JBiol Chem 275: 29179-29182.
16. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. 1998. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79: 129-168.
17. 2+ signal in brain. Prog Brain Res 56: 257-286.
18. Ding Q, Markesbery WR, Cecarini V, Keller JN. 2006. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem Res 31: 705-710.
19. Fountoulakis M, Cairns N, Lubec G. 1999. Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 57: 323-335.
20. Fu H, Subramanian RR, Masters SC. 2000. 14-3-3 Proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40: 617-647.
21. Galloway PG, Mulvihill P, Siedlak S, Mijares M, Kawai M, Padget H, Kim R, Perry G. 1990. Immunochemical demonstration of tropomyosin in the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 137: 291-300.
22. George JM. 2002. The synucleins. Genome Biol 3: 3002.
23. Green KN. 2009. Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. J Cell Mol Med 13: 2787-2799.
24. Gunning P, O'Neill G, Hardeman E. 2008. Tropomyosin-based regulation of the actin cytoskeleton in time and space. Physiol Rev 88: 1-35.
25. Hart GW. 1997. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Annu Rev Biochem 66: 315-335.
26. Hart GW, Kreppel LK, Comer FI, Arnold CS, Snow DM, Ye Z, Cheng X, DellaManna D, Caine DS, Earles BJ, Akimoto Y, Cole RN, Hayes BK. 1996. O-GlcNAcylation of key nuclear and cytoskeletal proteins: reciprocity with O-phosphorylation and putative roles in protein multimerization. Glycobiology 6: 711-716.
27. Hart GW, Housley MP, Slawson C. 2007. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446: 1017-1022.
28. Hoozemans JJ, Veerhuis R, Van Haastert ES, Rozemuller JM, Baas F, Eikelenboom P, Scheper W. 2005. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol 110: 165-172.
29. Hoozemans JJ, Stieler J, van Haastert ES, Veerhuis R, Rozemuller AJ, Baas F, Eikelenboom P, Arendt T, Scheper W. 2006. The unfolded protein response affects neuronal cell cycle protein expression: implications for Alzheimer's disease pathogenesis. Exp Gerontol 41: 380-386.
30. Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P, Scheper W. 2009. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am J Pathol 174: 1241-1251.
31. Hoyer S. 2004. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol 541: 135-152.
32. Issad T, Kuo M. 2008. O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab 19: 380-389.
33. Ji L, Chauhan A, Muthaiyah B, Wegiel J, Chauhan V. 2009. Gelsolin levels are increased in the brain as a function of age during normal development in children that are further increased in Down syndrome. Alzheimer Dis Assoc Disord 23: 319-322.
34. Kang HS, Welch WJ. 1991. Characterization and purification of the 94-kDa glucose-regulated protein. J Biol Chem 266: 5643-5649.
35. Khachaturian ZS. 1989. Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann N Y Acad Sci 568: 1-4.
36. Klee CB, Crouch TH, Richman PG. 1980. Calmodulin. Annu Rev Biochem 49: 489-515.
37. Krebs MP, Noorwez SM, Malhotra R, Kaushal S. 2004. Quality control of integral membrane proteins. Trends Biochem Sci 29: 648-655.
38. Lefebvre T, Dehennaut V, Guinez C, Olivier S, Drougat L, Mir AM, Mortuaire M, Vercoutter-Edouart AS, Michalski JC. 2010. Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1800: 67-79.
39. Li T, Paudel HK. 2007. 14-3-3Zeta facilitates GSK3beta-catalyzed tau phosphorylation in HEK-293 cells by a mechanism that requires phosphorylation of GSK3beta on Ser9. Neurosci Lett 414: 203-208.
40. Licastro F, Chiappelli M, Grimaldi LM, Morgan K, Kalsheker N, Calabrese E, Ritchie A, Porcellini E, Salani G, Franceschi M, Canal N. 2005. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiol Aging 26: 449-453.
41. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. 2004. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 101: 10804-10809.
42. Marcum JM, Dedman JR, Brinkley BR, Means AR. 1978. Control of microtubule assembly-disassembly by calcium-dependent regulator protein. Proc Natl Acad Sci U S A 75: 3771-3775.
43. Markesbery WR. 1997. Neuropathological criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 18(Suppl): S13-S19.
44. Maurer HH, Peters FT. 2005. Toward high-throughput drug screening using mass spectrometry. Ther Drug Monit 27: 686-688.
45. McGeer PL, Akiyama H, Itagaki S, McGeer EG. 1989. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 107: 341-346.
46. Mebane-Sims I. 2009. Alzheimer's disease facts and figures. Alzheimers Dement 5: 234-270.
47. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. 2000. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20: 3214-3220.
48. Nyakern-Meazza M, Narayan K, Schutt CE, Lindberg U. 2002. Tropomyosin and gelsolin cooperate in controlling the microfilament system. J Biol Chem 277: 28774-28779.
49. Owen JB, Di Domenico F, Sultana R, Perluigi M, Cini C, Pierce WM, Butterfield DA. 2009. Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. J Proteome Res 8: 471-482.
50. Peyrl A, Weitzdoerfer R, Gulesserian T, Fountoulakis M, Lubec G. 2002. Aberrant expression of signaling-related proteins 14-3-3 gamma and RACK1 in fetal Down syndrome brain (trisomy 21). Electrophoresis 23: 152-157.
51. Quadroni M, James P, Carafoli E. 1994. Isolation of phosphorylated calmodulin from rat liver and identification of the in vivo phosphorylation sites. J Biol Chem 269: 16116-16122.
52. Ritchie A, Morgan K, Kalsheker N. 2004. Allele-specific overexpression in astrocytes of an Alzheimer's disease associated alpha-1-antichymotrypsin promoter polymorphism. Brain Res Mol Brain Res 131: 88-92.
53. Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E. 2001. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 914: 48-56.
54. Sacks DB, Davis HW, Williams JP, Sheehan EL, Garcia JG, McDonald JM. 1992. Phosphorylation by casein kinase II alters the biological activity of calmodulin. Biochem J 283: 21-24.
55. Selkoe DJ. 2004. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6: 1054-1061.
56. 2+/calmodulin signaling system in the neural response to excitability. Involvement of neuronal and glial cells. Prog Neurobiol 58: 207-232.
57. Stamm S, Casper D, Lees-Miller JP, Helfman DM. 1993. Brain-specific tropomyosins TMBr-1 and TMBr-3 have distinct patterns of expression during development and in adult brain. Proc Natl Acad Sci U S A 90: 9857-9861.
58. Takahashi Y. 2003. The 14-3-3 proteins: gene, gene expression, and function. Neurochem Res 28: 1265-1273.
59. Thongboonkerd V, McLeish KR, Arthur JM, Klein JB. 2002. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 62: 1461-1469.
60. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, Nomura Y, Lipton SA. 2006. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441: 513-517.
61. Van Nostrand WE, Porter M. 1999. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38: 11570-11576.
62. Vembar SS, Brodsky JL. 2008. One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 9: 944-957.
63. Vosseller K, Hansen KC, Chalkley RJ, Trinidad JC, Wells L, Hart GW, Burlingame AL. 2005. Quantitative analysis of both protein expression and serine/threonine post-translational modifications through stable isotope labeling with dithiothreitol. Proteomics 5: 388-398.
64. Wells L, Vosseller K, Cole RN, Cronshaw JM, Matunis MJ, Hart GW. 2002. Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol Cell Proteomics 1: 791-804.
65. Wu JC, Liang ZQ, Qin ZH. 2006. Quality control system of the endoplasmic reticulum and related diseases. Acta Biochim Biophys Sin 38: 219-226.
66. Yaffe MB. 2002. How do 14-3-3 proteins work? Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett 513: 53-57.
67. Yamaguchi S, Meguro K, Itoh M, Hayasaka C, Shimada M, Yamazaki H, Yamadori A. 1997. Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer's disease as shown by MRI and PET. J Neurol Neurosurg Psychiatry 62: 596-600.